Comment by phil

View Single Comment

phil
April 22nd, 2014 at 8:04 pm
More color on Lilly/Novartis deal
12:50 PM ET · LLY
• Eli Lilly’s (LLY -0.9%) all-cash $5.4B acquisition of Novartis (NVS +1.4%) Animal Health makes Elanco the world’s second-largest animal health company.
• The purchase will be made with $3.4B of cash on hand and $2B in debt.
• Lilly expects to wring out $200M (~10%) in annual cost savings within three years of the expected Q1 2015 close.
• It forecasts EBIT yield in the mid-20% range by 2018.
• The transaction will be accretive to earnings on a cash basis starting in 2016, exclusive of integration costs.
• Management does not expect the deal to change the firm’s dividend policy or current share repurchase program.
var isMC=true; var adSize=’320×50′; var ord = Math.floor(Math.random()*10e12); var seekingalpha_ad_src=’http://ad.doubleclick.net/N6001/adj/sek.mobile/app;sz=320×50,320×250;x=x;tile=1;d=mobile;t=app;mcid=true;mcid=1685673;s=LLY;s=NVS;’+dart_my_vocation_and_profiles()+’ord=’+ord+’;dev=ip?’; document.write(”);